SCHEMBL19784012

SCHEMBL19784012

CCOC(=O)c1cn(-c2ncc(F)cc2F)c2nc(Cl)ccc2c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
THRB P10828 1/20 0.43
ALDH1A1 P00352 4/20 0.42
TSHR P16473 1/20 0.42
LMNA P02545 2/20 0.41
STAT3 P40763 2/20 0.40
HTT P42858 1/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
MAPK1 P28482 1/20 0.40
POLB P06746 2/20 0.39
TDP1 Q9NUW8 1/20 0.38
CSF1R P07333 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
ROCK2 O75116 1/20 0.38
CDK1 P06493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19784159 0.93 ALDH1A1 (0.42) MAPTTHRBALDH1A1TSHRLMNA
SCHEMBL19986915 0.88 STAT3 (0.43) MAPTTHRBALDH1A1TSHRLMNA
SCHEMBL18313042 0.86 MAPT (0.45) MAPTTHRBALDH1A1TSHRLMNA
SCHEMBL19783904 0.86 ALDH1A1 (0.41) MAPTALDH1A1TSHRLMNASTAT3
SCHEMBL7579922 0.85 MAPT (0.51) MAPTTHRBALDH1A1TSHRLMNA
SCHEMBL19784152 0.85 EPHA2 (0.46) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL19783901 0.85 EPHA2 (0.38) MAPTTHRBALDH1A1LMNAHTT
SCHEMBL19783491 0.85 KMT2A (0.39) MAPTTHRBALDH1A1TSHRLMNA
SCHEMBL18313615 0.84 MAPT (0.43) MAPTTHRBALDH1A1TSHRLMNA
SCHEMBL19784029 0.83 MAPT (0.41) MAPTTHRBALDH1A1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3481823-B1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF Bayer Pharma AG (DE) 2020-10-28 EP disclosed
US-20190241562-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-08 US disclosed
US-20190241562-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-08 US disclosed
WO-2018011017-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241562-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF GLS, TNNI3, AADAC MAPT 4293/4885THRB 3137/4885ALDH1A1 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.